New pill aims to slow lung scarring in IPF patients
NCT ID NCT07600021
First seen May 21, 2026 · Last updated May 21, 2026
Summary
This study tests whether the experimental drug SYH2059 can help adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and makes breathing harder. About 156 participants will receive either SYH2059 or a placebo, and researchers will measure changes in lung function over time. The goal is to see if the drug can slow the decline in lung capacity and improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.